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Abstract: The contribution of virus components to liberation of herpes simplex virus type 2 (HSV-2)
progeny virions from the surface of infected cells is poorly understood. We report that the HSV-
2 mutant deficient in the expression of a mucin-like membrane-associated glycoprotein G (mgG)
exhibited defect in the release of progeny virions from infected cells manifested by ~2 orders of
magnitude decreased amount of infectious virus in a culture medium as compared to native HSV-2.
Electron microscopy revealed that the mgG deficient virions were produced in infected cells and
present at the cell surface. These virions could be forcibly liberated to a nearly native HSV-2 level
by the treatment of cells with glycosaminoglycan (GAG)-mimicking oligosaccharides. Comparative
assessment of the interaction of mutant and native virions with surface-immobilized chondroitin
sulfate GAG chains revealed that while the mutant virions associated with GAGs ~fourfold more
extensively, the lateral mobility of bound virions was much poorer than that of native virions. These
data indicate that the mgG of HSV-2 balances the virus interaction with GAG chains, a feature critical
to prevent trapping of the progeny virions at the surface of infected cells.
Keywords: herpes simplex virus type 2; glycoprotein mgG; mucin-like protein; virus release; gly-
cosaminoglycans; single particle analysis
1. Introduction
The initial interaction of many different viruses with cells occurs via binding to ubiq-
uitous cell surface carbohydrate components such as sialic acid residues or glycosamino-
glycan (GAG) chains of proteoglycans. However, the same sugar receptor residues that
facilitate the virus binding to cells may serve as a trap that precludes the release of progeny
virions from the surface of infected cells. Some viruses that bind to sialic acid for example,
influenza viruses encode the receptor-destroying enzyme sialidase [1,2], and studies using
both a sialidase inhibitor [3] and virus mutants defective in sialidase activity [4] demon-
strated the presence of large clumps of progeny virus particles trapped at the cell surface
and cross-linked via sialic acid of their own envelope glycoproteins. Because the virus re-
lease from infected cells was vulnerable to antiviral intervention [3] it is not surprising that
the drugs currently approved for the treatment of influenza virus infections are inhibitors
of sialidase [5].
A number of viruses, including herpes simplex virus (HSV) [6], target GAG chains
of heparan sulfate (HS) and chondroitin sulfate (CS) for efficient attachment of virus
particles to cells. HSV-1 binding to HS requires a dodecasaccharide fragment of an HS
chain comprising a minimum of one 2-O- and one 6-O-sulfate group at specific spacing [7],
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while the binding of this virus to CS chains was greatly promoted by the presence of
CS-E units [8]. In contrast to extensive studies reported on the virus attachment to cell
surface GAG chains (reviewed in [9]), little is known of how the virus-GAG interaction is
balanced at the stage of the release of progeny virions from the surface of infected cells.
In this respect, it is worth noting that the synthesis of many cellular proteins, including
those that could trap viral particles at the cell surface, such as tetherin [10,11], is efficiently
shut off during the course of HSV infection of cells. However, the expression of the
GAG-bearing proteoglycans, such as some syndecans, was found to be either up- [12] or
down-regulated [13] by different herpesviruses. Although a number of different viruses
can interact with GAG chains, no GAG-degrading enzymatic activity encoded by a virus
has so far been reported. Instead, Hadigal et al. [14] found that the expression of cellular
heparanase, an HS-degrading enzyme, was enhanced in cells infected with HSV, and that
the knockdown of the heparanase gene decreased release of HSV-1 particles from the
surface of cultured cells by ~2–4 fold. We have previously found that the GAG mimetics
muparfostat (formerly known as PI-88) and heparin targeted the glycoprotein components
of HSV that comprise numerous and clustered O-linked glycans, known as mucin-like
regions. In particular, HSV-1 variants resistant to GAG mimetics expressed gC lacking an
entire amino-terminal mucin-like region [15] while HSV-2 variants were deficient of gG [16],
a glycoprotein derived from proteolytic cleavage of a precursor into a mature cell- and
virion membrane-associated fragment (mgG) that comprises mucin-like structures, and a
secreted fragment (sgG) [17–20]. These observations indicate that the mucin-like domains
of gC of HSV-1 and mgG of HSV-2 play a key role in determining the specific sensitivity
of respective virus to GAG mimetics and are most likely involved in the regulation of
the virus-GAG interplay at different stages of the HSV life cycle. The sgG was found to
potentiate the chemokine function [21] through the stabilization of chemokine receptor [22].
We have previously found that the mgG-deficient mutant of HSV-2 produced little
amounts of infectious virus in the supernatant medium of infected cells [16]. In the present
work, we investigated whether mgG of HSV-2 could promote the release of virus particles
from infected cells. Our study demonstrated that (i) the mgG deficient HSV-2 virions
were present on the surface of infected cells but were poorly released into the supernatant
medium; (ii) the GAGs or their mimetics such as muparfostat or heparin could liberate
these virus particles almost to the native HSV-2 level, and that (iii) the mgG deficient
mutant virus exhibited increased binding to GAG chains, but poorer lateral mobility of
bound virions in comparison to native HSV-2, suggesting that this interaction was greatly
unbalanced and shifted towards the trapping of viral particles on the GAG chains.
2. Materials and Methods
2.1. Materials
The muparfostat (previously denoted as PI-88) was provided by Progen Pharmaceu-
ticals Ltd., Brisbane, Australia and Medigen Biotechology Corporation, Taipei, Taiwan.
Heparin was obtained from Medicarb (Stockholm, Sweden). Methyl-3H-thymidine (20
µCi/mL; specific activity 6.7 Ci/mmole) and Na235SO3 (Sulfur-35 radionuclide, specific
activity 1050–1600 Ci/mmole) were purchased from Perkin Elmer. Mucin type I-S from
bovine submaxillary glands was obtained from Sigma-Aldrich (St. Louis, MO, USA)
(M3895). Monoclonal antibody 4A5A9 against glycoprotein sgG of HSV-2, which recognizes
linear epitope 206-APPQA-210 [23] and monoclonal antibody O1C5 (anti-glycoprotein mgG
of HSV-2), whose reactivity was mapped to linear epitope 557-HRGGPEE-563 [24], were
prepared as described previously [23,24]. Monoclonal antibodies B11D8 (anti-glycoprotein
gB of HSV) and B1E6 (anti-glycoprotein gE of HSV) were identified as specific for respective
proteins by radioimmunoprecipitation and/or western blot as described previously [25].
Monoclonal antibody E5F7 that recognizes glycoprotein gC of HSV-2 in immunoaffinity
chromatography [16] was also used. Stocks of anti-gB, anti-gC, anti-gE and anti-gG mono-
clonal antibodies were prepared by growing hybridoma cells in dialysis tubing [26]. Rat
polyclonal anti-Us3 protein of HSV was raised against baculovirus-expressed GST-Us3
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fusion protein and its specificity was confirmed by western blot [27]. This antiserum was
kindly provided by Dr. B. Banfield, Department of Microbiology and Immunology, Queen’s
University, Kingston, Canada.
2.2. Cells and Viruses
African green monkey kidney (GMK AH1) cells [28], obtained from the Swedish
Institute for Infectious Disease Control, Stockholm, were cultivated in Eagle’s minimum
essential medium (EMEM) supplemented with 2% fetal calf serum (FCS), 0.05% Primaton
RL substance (Kraft Inc., Norwich, CT, USA), 60 µg/mL of penicillin and 100 µg/mL
of streptomycin. Vero, human laryngeal epidermoid carcinoma (HEp-2), human skin
keratinocytes (HaCaT) [29], and murine L and mutant sog9 [30] cells were propagated in
Dulbecco’s modified EMEM supplemented with 10% fetal calf serum, 1% L-glutamine, 1%
tricine (Vero) and antibiotics. HEp-2 cells were obtained from the Swedish Institute for
Infectious Diseases Control, Stockholm. HaCaT cells were obtained from Dr. N.E. Fusenig,
German Cancer Research Center, Heidelberg. Murine L and sog9 cells were obtained
from Dr. F. Tufaro, University of British Columbia, Vancouver. All cell lines used were
free from mycoplasma contamination. The HSV-2 strain 333 (wt333) was used [31]. The
mgG deficient mutant viruses designated 333 + AC9gG (mgG-def) and 333 + AC3gG were
prepared by molecular transfer of a PCR amplified fragment encompassing nucleotides 222–
2140 of the gG gene into wt333 as previously described [16]. These specific fragments of
the gG gene were derived from the mgG deficient AC9 and AC3 variants of wt333, selected
by the virus passage in GMK AH1 cells in the presence of the sulfated oligosaccharide
muparfostat [16]. The virus variant AC9 was mgG deficient due to the deletion of a single
cytosine at position 1655 (GenBank accession number EU018128) resulting in a frameshift
and a premature stop codon at nucleotides 1924–1926 while the lack of expression of
mgG in AC3 variant was due to insertion of cytosine at position 624 (GenBank accession
number EU018100) with premature termination codon at nucleotides 919–921 [16]. The
virus recombinant mgG-def + AC9gG (mgG-res), in which the mgG expression was rescued
by cotransfection into GMK AH1 cells of the gG gene fragment (nucleotides 222–2140) of
wt333 with the mgG-def DNA, was prepared in a similar manner to the mgG deficient
recombinant viruses.
2.3. Purification of HSV-2 Virions, Glycoprotein gG, and Quantification of Viral DNA
The virus particles were radiolabeled with methyl-3H-thymidine (20 µCi/mL) and
were purified from infectious extracellular medium and infected GMK AH1 cells by
centrifugation through a three-step discontinuous sucrose gradient as described previ-
ously [16,32]. Glycoprotein sgG was purified from infectious culture supernatant of in-
fected GMK AH1 cells using the monoclonal antibody 4A5A9 coupled to CNBr-Sepharose
beads [23]. Quantification of viral DNA was performed based on real-time PCR analysis as
described previously [33].
2.4. Virus Replication Kinetics and Forcible Virus Liberation Assays
The GMK AH1 cells growing in 12 well plates were rinsed twice with 1 mL of EMEM
and inoculated with HSV-2 at a multiplicity of infection (moi) of 2. Following incubation
of cells with the virus for 2 h at 37 ◦C, the cells were rinsed thrice with 1 mL of EMEM
and were incubated for a further 8–24 h in the same medium. The infectious culture
medium was harvested and centrifuged at 200× g for 5 min. The amount of virus in the
supernatant medium was determined by the plaque titration assay [34,35]. The infected
cells were gently rinsed thrice with the medium, then scrapped into 1 mL of the medium
and subjected to two rapid freeze-thaw cycles at −80 ◦C ethanol and 37 ◦C water bath,
respectively, to release the cell-associated virus. Following centrifugation at 500× g for
5 min, the amount of infectious virus in the supernatant medium was determined by the
plaque titration assay. The assay of forced liberation of infectious virus from the surface of
infected cells was performed as follows. The GMK AH1 cells were infected with HSV-2 as
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specified above, and then incubated in EMEM, which at specific times after infection was
supplemented with the sulfated oligosaccharide muparfostat, the sulfated polysaccharide
heparin, sgG, or with type I-S mucin from bovine submaxillary glands. The area of viral
plaques was determined [16] to reflect the cell-to-cell spread of the virus. Briefly, images
of at least 20 neighboring viral plaques were captured using a DC300 digital camera
(Leica, Heerbrugg, Switzerland) attached to a Diavert microscope with ×2.5 magnification
objective (numerical aperture 0.08) (Leitz-Wetzlar, Wetzlar, Germany), and the area of viral
plaques was measured using the IM500 software (Leica, Cambridge, UK).
2.5. Total Internal Reflection Fluorescence Microscopy
End-on surface immobilization of biotinylated GAGs hyaluronan (b-HA, 23 kDa, IN-
NOVENT e.V., Jena, Germany) and chondroitin sulfate (b-CS; mixture of 70% chondroitin-
4-sulfate (CS-A) and 30% chondroitin-6-sulfate (CS-C), 20 kDa, INNOVENT e.V., Jena,
Germany) was used to study the binding affinity of wt333 and mgG-def to GAGs. Briefly,
supported lipid bilayers containing 1-palmitoyl-2-oleoyl-sn glycero-3-phosphocholine
(POPC) and 1% (w/w) 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N (cap biotinyl)
(DOPE-cap-biotin) were formed from a 0.5 mg/mL liposome suspension on cleaned cover
glasses by surface-induced vesicle rupture. The liposomes were produced by the lipid
hydration and extrusion method using 30 nm membranes, as described previously [36].
The supported lipid bilayers were incubated with streptavidin (Sigma-Aldrich) for 20 min
at a concentration of 25 µg/mL, followed by a 20 min incubation with b-HA (0.2 mg/mL)
or b-CS (0.5 mg/mL). The sample was rinsed extensively between each incubation step.
In all cases, PBS (137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4, 1 mM
CaCl2 and 0.5 mM MgCl2) was used as a buffer.
Preparations of purified wt333 and mgG-def virus particles were fluorescently la-
beled with PKH26 red fluorescent cell linker dye (Sigma-Aldrich). To this end, the virus
suspension was mixed with a 0.5 mM dye-in-ethanol solution in presence of Diluent C
(Sigma-Aldrich), which served as a diluting agent (the final virus and dye concentrations
were 5.6% (v/v) and 0.3% (v/v) respectively). Excess dye was removed by 1-min centrifuga-
tion at 2000× g through llustra Microspin S-200 HR columns (GE Healthcare, Chicago, IL,
USA). Ten microliters of the fluorescently labeled virus particle suspension were added to
the GAG-functionalized surfaces (covered with 5 µL of PBS) at approximately 60 min prior
to the beginning of the measurements in order to reach equilibrium conditions. One hour
time-lapse movies (250 frames, 15-s time interval) were recorded with a Nikon Eclipse Ti-E
inverted microscope using a 60× magnification oil immersion objective (numerical aper-
ture = 1.49), an Andor DU879E-CSBV camera, an X-Cite 120 light source (Lumen Dynamics
Group Inc., Mississuaga, ON, Canada), and a TRITC Filter Cube (Nikon, Tokyo, Japan).
For each surface, time-lapse movies were recorded at 5 different locations on the surface.
The time-lapse movies were analyzed with in-house written MATLAB (The MathWorks,
Natick, MA, USA) scripts for both Equilibrium Fluctuation Analysis and Single Particle
Tracking (SPT) as follows. To extract information on binding kinetics, we used equilibrium
fluctuation analysis [37]. Briefly, the software counts the number of newly arrived particles
for each frame and measures their individual residence times. It then generates two figures:
a cumulative plot of newly bound particles over time, from which we extracted association
rates (slope of the linear fit of the association curve), and a histogram of residence times,
from which one can obtain information on the dissociation behavior of the particles (as
further described in [38]). The obtained association rates were pooled for all 5 recorded
positions and divided by the total imaged area and the final viral concentrations of purified
viral suspensions in molar according to DNA count (3.7 × 1010 DNA copies/mL for wt333
stock solution and 3.8 × 109 DNA copies/mL for mgG-def stock solution). Thus, the slope
obtained from the linear fit of the normalized association data can be used to directly
compare, qualitatively, the association rate constant (kon) of both viruses. For each dataset,
association rates of the mgG-def virus mutant were divided by the association rates of the
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wt333 strain. Averages of the normalized association rates were calculated over 3 datasets
and presented with standard deviations.
The recorded time-lapse movies were further analyzed using SPT to quantify particle
mobility. Briefly, detected particles between two consecutive frames were linked to con-
struct particle trajectories for which we calculated the mean square displacements (MSDs)
values for a range of lag times ∆t. The MSD-∆t plots were then fitted using a model for
normal diffusion and a model for anomalous diffusion, to extract diffusion coefficients
D of the surface bound HSV-2 particles (as further described in [38]). Particles with D
values higher than a chosen threshold value (10−4.5 µm2/s for anomalous diffusion and
10−6.1 µm2/s for normal diffusion) were considered as mobile and served to determine the
overall mobile fraction, averaged over 3 datasets and represented with standard deviations.
2.6. Binding of Virus to Infected Cells
GMK AH1 cells growing in 12 well plates were rinsed twice with 1 mL of EMEM and
inoculated with HSV-2 at moi of 1. Following incubation of cells with the virus for 2 h at
37 ◦C, the cells were rinsed twice with 1 mL of EMEM and incubated in the same medium
for further 22 h. The cells were then gently rinsed with warm EMEM and 1 mL of the
same medium comprising viral particles of purified radiolabeled mgG-def or wt333 (both
at ~1.7 × 107 of DNA copies) was added to and incubated with cells for 2 h at 37 ◦C. The
cells were then gently rinsed thrice with PBS, solubilized in 0.3 mL of 5% SDS [39], and
transferred to scintillation vials for quantification of radioactivity.
2.7. Immunogold Electron Microscopy
The HaCaT cells growing in 24 well plates on a Melinex polyester membrane (Agar
Scientific Ltd., Stansted, UK) were inoculated with HSV-2 at a moi of 10. After 20 h of
infection at 37 ◦C, the culture medium was removed and cells rinsed once with PBS. The
cells were then fixed with 0.25% glutaraldehyde in PBS for 1 h at room temperature. The
fixative was removed and the cells were rinsed four times with 1 mL of PBS. Following a
1 h period of blocking of cells with 10% FCS in PBS, 1 mL portions of the same medium
comprising 100 µL of monoclonal antibody B11D8 (anti-gB), B1E6 (anti-gE), E5F7 (anti-
gC2), or O1C5 (anti-mgG) were added and incubated for 5 h at room temperature under
gentle rocking. The cells were then rinsed four times with 1 mL of PBS, and 0.2 mL of
PBS supplemented with 10% FCS and 50 µL of the 6 nm gold particle-conjugated F(ab’)2
fragment of goat-anti-mouse IgG (Aurion, Hatfield, PA, USA) was added and incubated
overnight at 4 ◦C under gentle rocking. The cells were then rinsed four times with PBS and
fixed with 1 mL of 2.5% glutaraldehyde in PBS for 1 h at room temperature. Following
rinsing with 0.05 M Tris-HCl buffer (pH 7.4) supplemented with 2 mM CaCl2, the cells
were processed for electron microscopy as described by Widehn and Kindblom [40]. The
CM10 transmission electron microscope (Philips) was used, and images were captured
using the iTEM Image Analysis Platform (Olympus).
2.8. Assay to Detect a GAG Lyase Activity
Searching for putative GAG lyase activity in HSV-2 was performed by mixing in PBS
the purified radiolabeled GAG chains with purified non-labeled HSV-2 particles. The
virus-GAGs mixture was incubated for 20 h at 37 ◦C, then clarified by centrifugation at
16,000× g for 10 min, and the supernatant was centrifuged over filters with 10 kDa cut off.
To search for the possible degradation of GAG chains, the radioactivity was quantified
in both the pass-through and the filter-retained samples. The GAG chains were also
mixed with heat-inactivated (95 ◦C for 5 min) purified HSV-2 and processed in the same
manner to serve as controls. The GAG samples, used in this experiment, were prepared as
follows. GMK AH1 cells, seeded the day prior to experiment, were rinsed and incubated
for 48 h at 37 ◦C in sulfate-free EMEM supplemented with 10% normal EMEM, 5% FCS,
antibiotics, and 20 µCi/mL of Na235SO3 (Sulfur-35 radionuclide, specific activity 1050–
1600 Ci/mmole, Perkin Elmer). The medium was removed, the cells rinsed twice with
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EMEM, and the cell-associated GAG chains (proteoglycans) were released from the cell
surface by incubation with trypsin (1 mg/mL) in PBS for 15 min at 37 ◦C. The cell debris
was pelleted by centrifugation at 5000× g for 5 min, and the supernatant was run through
a DEAE-Sephacel column equilibrated with 0.3 M NaCl in 0.2 M phosphate buffer, pH
7.0. Following excessive washing of beads with the same buffer, the retained material was
eluted with 2 M NaCl in 0.2 M phosphate buffer. The fractions exhibiting high radioactivity
were pooled and incubated at 95 ◦C for 15 min to inactivate any residual enzymatic activity.
The rest of the procedure was carried out as described previously [8,41], except that the
treatment step with either heparinase or chondroitinase ABC was omitted to retain both
HS and CS chains. The GAG preparation was centrifuged through filters (cut off 10 kDa),
and the filter-retained material was solubilized in redistilled water and stored at −80 ◦C.
2.9. Preparation of Cellular Extracts, Electrophoresis, and Immunoblot Assay
Extract of infected GMK AH1 cells was prepared and processed for electrophoresis as
described by Finnen et al. [27]. Samples were electrophoresed under reducing conditions
on a 4–12% NuPAGE Bis-Tris precast gel (Novex, Carlsbad, CA, USA) and then transferred
into PVDF membrane. Detection of viral Us3 and mgG components was performed at a
1:1000 dilution of rat polyclonal anti-Us3 serum [27] and at a 1:500 dilution of monoclonal
anti-mgG antibody O1C5 respectively. Peroxidase-conjugated F(ab)2 fragments of goat
anti-rat or goat anti-mouse IgG (Jackson ImmunoResearch Labs, West Grove, PA, USA)
were used at a dilution of 1:1000, and 4-chloro-1-naphtol was used as a substrate.
2.10. Statistical Analysis
Multiple unpaired t-test (GraphPad Prism 9.0.2) was used. Experimental data showing
the virus titers were transformed into log10 values.
3. Results
3.1. Biological Activities of the mgG Deficient Mutant of HSV-2
We have found previously that the recombinant virus 333 + AC9gG (mgG-def), which
is deficient in the mucin-like protein mgG expression due to a frameshift mutation, pro-
duced very low amounts of virus in an infectious culture supernatant medium [16]. In
the present study, we repeated this experiment but in addition to the mgG-def mutant
virus and native wild-type 333 (wt333) strain of HSV-2, we also used a recombinant virus
mgG-def + wt333gG (mgG-res) in which the gG expression was rescued by the molecular
transfer of the gG gene fragment from wt333 into the DNA of the mgG-def virus mutant.
GMK AH1 cells were inoculated with these viruses at a moi of 2 plaque forming units (PFU)
per cell, and the yield of infectious virus was assessed in the culture supernatant medium
and in infected cells at different time points post inoculation (p.i.). Although the production
of mgG-def mutant virus in cells was ~4–6 times lesser than that of wt333 in all time-points
after inoculation (Figure 1A), the amount of infectious virus that spontaneously released
from cells into the supernatant culture medium was decreased by more than 2 orders of
magnitude (Figure 1B). Importantly, the mgG-res, that is, a recombinant virus prepared
by the restoration of mgG in the mgG-def mutant virus, produced infectious virus in cells
and in culture supernatant in quantities similar to that of wt333 (Figure 1A,B), indicating
that the expression of mucin-like protein mgG conferred the efficient release of HSV-2 from
cells. Importantly, the low infectious titer of the mgG-def in supernatant medium was not
due to the decreased infectivity of viral particles since the specific infectivity values (viral
DNA copies/PFU), determined in two preparations of purified virions, were only slightly
different, averaging 28 ± 12 for wt333 and 36 ± 21 for mgG-def virus.
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after infection of GMK AH1 cells from six different microscope fields.
Because viral gG and the Us3 protein kinase are expressed from the same bicistronic
gene we sought to verify whether frameshift mutations that are present in our mgG
deficient virus mutants, would affect the expression of Us3 protein. It has been reported
that insertions of relatively large DNA fragments into the gG gene of pseudorabies virus, a
related herpesvirus, reduced the expression of Us3 [42], a feature that would complicate
the interpretation of data obtained with the mgG deficient viruses. Immunoblot analysis of
lysates from infected GMK AH1 cells confirmed that mgG-def and another mgG deficient
recombinant virus 333 + AC3gG (AC3) did not express mgG (Figure 1C). This protein is
represented in wt333 as the high mannose intermediate (~72 kDa), and the O-glycosylated
mature forms of gG (mgG) of higher molecular masses. The expression of the Us3 protein
was investigated using polyclonal rat anti-Us3 serum that detects a protein of slightly
higher molecular mass than predicted for Us3 (~53 kDa) [27]. The mgG deficient mutant
viruses produced, like wt333, the Us3 protein (Figure 1C) indicating that the poor release
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of the mgG-def virions into extracellular medium was not due to the absence or alteration
in Us3 expression. Furthermore, we found that the mgG-def virus mutant formed plaques
of a size similar to that of wt333 (p = 0.08; n = 67) (Figure 1D), indicating that the low titer
of free viral particles was not due to major defects in replication or the cell-to-cell spread of
this virus.
The results shown in Figure 1 revealed that compared to wt333, the mgG-def mutant
virus produced in infected cells approximately 4–6 fold less infectious virus (Figure 1A)
which was poorly released into infectious culture medium (Figure 1B). To clarify this
issue, GMK AH1 cells infected with the mgG-def mutant virus or wt333, were analyzed
by electron microscopy (Figure 2A–F). The cells were propagated on Melinex polyester
membranes to be processed for electron microscopy without any scraping or pelleting. We
found that the mgG-def virus mutant (Figure 2B,D) produced, like wt333 (Figure 2A,C),
mature enveloped virions that were present on the surface of infected cells.
Since GMK AH1 cells infected with mgG-def produced ~4–6-fold less infectious
virus than cells infected with wt333 (Figure 1A), one could expect similar decrease in
the mgG-def virion quantity at the cell surface. However, the number of virions per cell,
counted on cell surface in images of six infected cells, averaged 58 ± 34 and 66 ± 17 for
mgG-def and wt333 respectively suggesting a similar accumulation of mgG-def and wt333
virions. The adherence of cells infected with wt333 and the mgG-def mutant virus to
the Melinex support membrane is shown in Figure 2E,F, respectively. To further search
for an explanation of the role of mgG in the virus infection of cells, we investigated the
expression of this glycoprotein at the surface of infected cells by using an immunogold
electron microscopy technique (Figure 3).
In cells infected with wt333, the mgG was expressed on the surface of virus particles
and on the cell plasma membrane including long cytoplasmic protrusions (Figure 3A,B).
As expected, this specific pattern of mgG labeling with gold particles was absent in cells
infected with the mgG-def virus mutant (Figure 3C). The viral glycoproteins gB (Figure 3D),
gC (Figure 3E), and gE (Figure 3F) were detected at the surface of viral particles, and the
expression of these components at the cell plasma membrane and cytoplasmic protrusions
was less abundant than that of mgG. These results indicate that the HSV-2 expresses ample
amounts of mgG on the plasma membrane of infected cells and in HSV-2 virions.
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Figure 3. Expression of mgG of HSV-2 at the surface of infected cells. HaCaT cells were inoculated
with the HSV-2 strain wt333 (A,B,D,E,F) or with the mgG-def virus mutant (C), and 24 h later the
cells were immunogold labeled using monoclonal antibodies specific for mgG (A–C), gB (D), gC (E)
or gE (F) followed by the 6 nm gold particle-conjugated F(ab’)2 fragment of goat-anti-mouse IgG.
The HSV-2 virions (arrow), cell plasma membrane (white arrowhead) or cellular protrusions (black
arrowhead) decorated with gold particles are indicated. The insets of enlarged virions are derived
from separate images.
3.2. Release of the mgG-def Virions from the Surface of Infected Cells
Knowing that the mgG-def virions are present on the surface of infected cells (Figure 2B),
we attempted to forcibly liberate infectious virus by treatment of cells with the following
agents: (i) Secreted fragment of gG (sgG) because gG of HSV-2 apart from the virion-
associated mgG also comprises sgG that is secreted from infected cells into the medium [19];
(ii) mucin from bovine submaxillary glands because mgG comprises an extensive mucin-
like region, and (iii) GAGs or their mimetics such as sulfated oligosaccharide muparfostat
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or sulfated polysaccharide heparin which are known to compete with cell surface GAG
chains of HS and CS for binding sites in HSV attachment proteins [16]. After infection
of cells for 2 h at 37 ◦C, the inoculum was carefully removed and the cells were rinsed
and incubated in medium supplemented with these agents for further 22 h, that is, until
the development of complete cytopathic effect. Only the GAG-mimicking compounds
liberated substantial amounts of infectious virus (Figure 4A). Although the mgG-def virus
is known to be relatively resistant to muparfostat and heparin, which was manifested as
~10 fold decreased sensitivity to these compounds as compared to wt333 [16], incubation
of cells with muparfostat and heparin (both at 5 µg/mL) substantially enhanced the level
of infectious virus in supernatant culture medium (Figure 4A). Remarkably, while the
level of wt333 and the mgG-res was enhanced by muparfostat ~6–7 fold, the amount of
mgG-def virus in the medium was increased ~200 fold, that is, nearly to the level found
with mock-treated wt333 (Figure 4B).




Figure 4. Forcible liberation of the mgG deficient HSV-2 from the surface of infected cells. (A) 
GMK AH1 cells were infected with the mgG-deficient (mgG-def) mutant virus at multiplicity of 
infection of 1 for 2 h at 37 °C, then rinsed twice with Eagle´s medium and incubated for further 22 
h in the same medium supplemented with specific concentrations of secreted gG (sgG) of HSV-2, 
mucin, heparin, and muparfostat. The concentrations of mucin were 2000 times higher than indi-
cated in the graph. (B) GMK AH1 cells were infected with HSV-2 strain 333 (wt333), the mgG-def, 
and the mgG-proficient recombinant virus (mgG-res) and then incubated with muparfostat (10 
µg/mL) as described above. (C) GMK AH1 cells were infected with the mgG-def as described in 
part (A) and subjected to short treatments with muparfostat (10 µg/mL) beginning at 24 h after 
infection. (D) Murine L and mutant sog9 cells as well as Vero, HEp-2 and GMK AH1 cells were 
infected with wt333 or the mgG-def, and the cells infected with the latter virus were subjected to 
muparfostat (10 µg/mL) treatment as described in part (A). The virus titers (PFU/mL) were quanti-
fied in infectious culture supernatant medium and all values shown are means (±SD) of data from 
two to four separate experiments performed in duplicates. Statistically significant differences at p 
values of <0.005 (***) or <0.05 (*). 
To discriminate whether these enhancing effects of the GAG-mimetic muparfostat 
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from the cell surface, the cell-free infectious culture supernatant of the mgG-def virus was 
mixed with muparfostat (10 µg/mL) and incubated for 1 h at 37 °C. The mean infectious 
titers found in three experiments were 7.2 × 103 and 6.9 × 103 PFU/mL for the muparfostat 
and mock treated samples respectively, indicating that muparfostat did not directly stim-
ulate infectivity of the mgG-def virions. Previously we have observed that muparfostat 
exhibited no permanent inactivation or enhancement of infectivity of wt333. To clarify 
whether muparfostat could release the mgG-def virus from the cell surface, infected cells 
(24 h p.i.) were subjected to a short muparfostat treatment. Muparfostat was capable of 
releasing substantial amounts of mgG-def virus already after 5 min of treatment (Figure 
4C). Because such a short duration of treatment may not be sufficient for uptake of mu-
parfostat and stimulation of virion exocytosis, we conclude that the mgG-def virions were 
present in substantial quantities at the cell surface and that muparfostat forcibly liberated 
them into the medium. 
Figure 4. orcible liberation of the gG deficient HSV-2 from the surface of infected cells. (A) GMK
AH1 cells were infected with the mgG-deficient (mgG-def) mutant virus at m ltiplicity of infection
of 1 for 2 h at 37 ◦C, then rinsed twice with Eagle´s medium and incubated for further 22 h in the
same medium supplemented with specific concentrations of secreted gG (sgG) of HSV-2, mucin,
heparin, and muparfostat. The concentrations of mucin were 2000 times higher than indicated in
the graph. (B) GMK AH1 cells were infected with HSV-2 strain 333 (wt333), the mgG-def, and the
mgG-proficient recombinant virus (mgG-res) and then incubated with muparfostat (10 µg/mL) as
described above. (C) GMK AH1 cells were infected with the mgG-def as described in part (A) and
subjected to short treatments with muparfostat (10 µg/mL) beginning at 24 h after infection. (D)
Murin L and mutant sog9 cells as well as Vero, HEp-2 and GMK AH1 cells were infected with wt333
or the mgG-def, and the cells infected with the latter virus were subjected to muparfostat (10 µg/mL)
treatment as described in part (A). The virus titers (PFU/mL) were quantified in infectious culture
supernatant medium and all values shown are means (±SD) of data from two to four separate
experiments performed in duplicates. Statistically significant differences at p values of <0.005 (***) or
<0.05 (*).
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To discriminate whether these enhancing effects of the GAG-mimetic muparfostat
were due to direct activation of infectivity of viral particles or facilitation of virus release
from the cell surface, the cell-free infectious culture supernatant of the mgG-def virus
was mixed with muparfostat (10 µg/mL) and incubated for 1 h at 37 ◦C. The mean
infectious titers found in three experiments were 7.2 × 103 and 6.9 × 103 PFU/mL for the
muparfostat and mock treated samples respectively, indicating that muparfostat did not
directly stimulate infectivity of the mgG-def virions. Previously we have observed that
muparfostat exhibited no permanent inactivation or enhancement of infectivity of wt333.
To clarify whether muparfostat could release the mgG-def virus from the cell surface,
infected cells (24 h p.i.) were subjected to a short muparfostat treatment. Muparfostat was
capable of releasing substantial amounts of mgG-def virus already after 5 min of treatment
(Figure 4C). Because such a short duration of treatment may not be sufficient for uptake of
muparfostat and stimulation of virion exocytosis, we conclude that the mgG-def virions
were present in substantial quantities at the cell surface and that muparfostat forcibly
liberated them into the medium.
Liberation of the mgG-def virions by GAG-mimetics suggested that these virions are
trapped on the cell surface due to their binding to GAGs, and that the mgG proficient wt333
but not mgG-def virus particles may somehow promote the virus release from cells. To
address this issue, we investigated whether wt333 virions express any GAG lyase activity
(heparanase, chondroitinase or sulfatase) that could liberate virus particles trapped at the
cell surface due to their binding to GAG chains. To this end, purified 35SO3 labeled GAG
chains (~100,000 cpm) were mixed with purified wt333 particles or with heat inactivated
(95 ◦C for 10 min) purified virus particles and incubated for 20 h at 37 ◦C. The mixtures
were then centrifuged over filters with a 10 kDa cut off. Because HS chains expressed in
GMK AH1 cells averaged 30 kDa in apparent molecular mass [7], we hypothesized that
any GAG lyase activity of HSV-2 may generate low molecular mass cleavage products of
GAG chains. By using this approach, we found that incubation of GAGs with both native
and heat-inactivated virus particles produced very low levels of filterable 35SO3 labeled
material (<40 cpm) with no clear difference between these two preparations. These data
suggest that HSV-2 has no GAG-destroying activity.
To investigate whether the expression of GAG chains would affect release of HSV-2
from infected cells we quantified both spontaneously released and muparfostat liberated
virus in the mutant sog9 cells derivative of the GAG proficient murine L cells. Sog9 cells
were originally reported to be deficient in expression of HS and CS GAG chains [30],
however, these cells were later found to still express CS chains which due to defect in
expression of chondroitin-4-O-sulfotransferase-1 were ~3 times shorter in chain length and
possessed decreased proportion of 4-O- and 4,6-O-sulfated disaccharide units but increased
proportion of 6-O-sulfated disaccharides as related to parental cell line [43]. GMK AH1,
Vero, and HEp-2 cells were also included in this experiment for comparative purposes
(Figure 4D). In comparison with wt333, the defect in release of mgG-def mutant virus from
cells was the most pronounced in GMK AH1 cells (~2 log10 decrease in infectious titer), and
it was also evident in Vero and murine L and sog9 cells (~1–1.5 log10). In HEp-2 cells the
amount of released mgG-def virus did not differ from that of wt333. Note that the lack of
difference between wt333 and the mgG-def in HEp-2 cells was not due to efficient liberation
of the mutant virus but rather owing to relatively poor release of wt333 from these cells.
Treatment of infected cells (including HEp-2 cells) with muparfostat substantially enhanced
the yield of mgG deficient virus in the supernatant medium (Figure 4D). Importantly, the
amounts of the mgG-def mutant virus in the supernatant medium of sog9 and L cells
were similar. Likewise, treatment of infected cells with muparfostat enhanced the yield
of extracellular virus in a similar way, that is, ~20 fold in sog9 and ~17 fold in L cells
(Figure 4D). These data indicate that the defect in release of mgG-def virions from cell
surface as well as their forcible liberation with GAG mimetic also occurred in sog9 cells
which do not express HS but produce CS chains [43].
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3.3. Interaction of mgG-def Virions with Surface-Bound CS Chains
To complement our data shown in Figure 4D with regards to a possible participation
of CS chains in interaction with the mgG-def mutant virus, and to further clarify contribu-
tion of mgG to the virus-GAG interaction, we used total internal reflection fluorescence
microscopy (TIRFM) to study the virus binding kinetics and mobility on surface-bound
CS (Figure 5). The GAG chains were end-grafted onto the sensor surface in a brush-like
architecture, in order to mimic the attachment of GAGs to proteoglycans. Hyaluronan
(HA), a non-sulfated GAG, was used as a negative control. The TIRFM-setup makes it
possible to visualize individual surface-bound particles while suppressing the fluorescent
background (Figure 5A), allowing for the analysis of virus binding and release events, as
well as their mobility, on a single particle level. In this study, the characteristics of the
interaction of mgG-def and wt333 with CS were compared.
First, to investigate the association behavior, we measured the rate of arrival of
particles to the sensor surfaces. Figure 5B shows association curves of wt333 and the
mgG-def mutant virus to CS and HA. On CS, the measured association rate for wt333
was 22.6% ± 3.9% of the association rate of the mgG-def. Both viruses showed very low
association to HA (~2.4% of association for mgG-def and ~1.1% for wt333 in comparison
to the respective association rates to CS), as expected, for a non-sulfated GAG [38]. For
reaction-limited binding kinetics, the measured association rates are directly proportional
to the association rate constants kon [38], which allows for a qualitative comparison of the
binding propensities of wt333 and the mutant virus. The observed differences in association
rates therefore indicate that the mgG-def mutant virus bound to CS approximately 4.5 times
more efficiently than wt333. Analysis of the dissociation behavior of the two viruses
revealed that once bound only very few virus particles (less than ~3% for both viruses)
detached from the CS layer, as observed previously for HSV-1 [38].
In addition to kinetic analysis, we performed single particle tracking (SPT) analysis
to quantify virus particle diffusion on the CS surfaces. Visual inspection of the recorded
movies revealed that a fraction of CS-bound HSV-2 particles underwent lateral diffusion
as illustrated by the individual particle trajectories shown in Figure 5C,D for the wt333
and mgG-def viruses, respectively. Moreover, the wt333 (Figure 5C) appeared to show
increased mobility compared to the mgG-def mutant virus (Figure 5D). To quantify this
visual observation, we calculated the diffusion coefficients corresponding to the measured
trajectories. Data in Figure 5E show the histograms of the calculated diffusion coefficients
for both viruses. Both histograms are dominated by a peak at ~10−8 µm2/s, which we
attributed to immobile particles. The non-zero value of this peak is caused by localization
errors of the particles [38]. In addition, the histograms show a large tail in the distributions
of D values with diffusion coefficients ranging up to ~10−1 µm2/s, which implies that a
few particles can travel distances up to 40 µm during the acquisition time of 1 h. The tail
distribution of wt333 particles showed higher frequencies at high D values compared to
mgG-def, which is in line with our initial observation that fast diffusing wt333 particles
were more numerous. To illustrate this, we further calculated for each virus the average
mobile fraction, determined by the percentage of particles with D values higher than
a threshold value, which we chose based on the position of the immobile peak in the
histograms (see Materials and Methods section for further details). We measured a mobile
fraction of 32.8 ± 2.7% for the wt333 strain and 19.1 ± 7.5% for the mgG-def mutant virus
(Figure 5F), confirming increased mobility for the wt333 in comparison to the mutant virus.
These data demonstrate that the mgG-def virions exhibited much more extensive binding
to CS chains compared to wt333 virions, a feature that may limit their lateral diffusion.
This suggests that mgG plays a role in balancing the interaction of HSV-2 particles with
GAG chains.
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Figure 5. TIRF microscopy to quantify HSV-2 binding and mobility to end-grafted GAG chains. (A) TIRF images showing
fluorescently labeled HSV-2 strain wt333 particles bound to chondroitin sulfate (CS) and hyaluronan (HA) (inset). Scale
bar: 50 µm. (B) Cumulative plot of newly bound particles over time, including linear fits, for the wt333 and mgG deficient
(mgG-def) mutant virus on CS and HA. The data was normalized to the virus concentration, yielding a slope proportional
to the association rate constant (kon) and allowing for a direct omparison of the assoc ation behavi r of both viruses. The
association curves were corrected to account for the differences in particle concentration of the two virus suspensions. (C,D)
Mobile trajectories of HSV-2 strain 333 (in C) and mgG-def (in D) on CS, determined by SPT analysis of a representative
TIRF movie. Scale bars: 20 µm. (E) Histograms of diffusion coefficients for HSV-2 333 and mgG-def particles diffusing
on CS. (F) Mobile fractions of wt333 and mgG-def viral particles diffusing on CS as determined from the histograms of
diffusion coefficients.
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Furthermore, because the mgG-def mutant virus exhibited extensive GAG-binding
activity (Figure 5B), we tested the binding of these virions to infected cells. HSV shuts off
the synthesis of most host cell proteins [44] to avoid their interference with the virus life
cycle including limitation in the re-binding of newly produced virions to infected cells.
GMK AH1 were inoculated with wt333 or were mock inoculated, and 24 h later purified
methyl-3H-thymidine labeled mgG-def or wt333 virions were added and incubated with
cells for 2 h. While wt333 bound more efficiently to non-infected than to infected cells,
the mgG-def virions exhibited similar binding efficacy in both kinds of cells (Figure 6).
These results suggest that interaction of the mgG-def virus mutant with cells is greatly
unbalanced, a defect manifested as efficient virus binding to infected cells.




Figure 6. GMK AH1 cells were inoculated with the strain wt333, and 24 h later purified methyl-
3H-thymidine labeled mgG deficient or wild type virions (adjusted to 1.7 × 107 DNA copies) were 
added and incubated with cells for 2 h at 37 °C. The results are expressed as a percentage of the 
number of counts per minute (cpm) bound to infected cells relative to that bound to non-infected 
control cells. Values shown are means (±SD) of data from two separate experiments performed in 
duplicates. The mean number of cpm bound to non-infected cells were 1053 and 554 for wt333 and 
mgG-def virions respectively. Statistically significant differences as related to uninfected cells at p 
values of <0.005 (***). 
4. Discussion 
We report that the mucin-like glycoprotein mgG of HSV-2 balances the virus inter-
action with GAG chains, a feature required for efficient release of progeny virions from 
the surface of infected cells. This conclusion is deduced from the following observations. 
The amount of infectious virus that was spontaneously released from cells into extracel-
lular medium was substantially decreased in the mgG deficient mutant virus as related to 
native HSV-2, a difference reversed to native HSV-2 level by restoration of the mgG ex-
pression in the virus mutant. This difference cannot be attributed to a defect in production 
of infectious virus since a total yield of the mgG deficient mutant was only ~4–6 times 
lower than that of native HSV-2. Moreover, our data exclude the possibility that the poor 
release of mgG deficient HSV-2 from cells was caused by an altered production of viral 
Us3, a protein expressed from the same bicistronic gene as gG. It is not known whether 
the coupled expression of Us3 and gG has any biological significance, however, Us3 pro-
tein kinase is a known anti-apoptotic component of HSV-2 [45]. 
How does the mgG of HSV-2 promote release of virus particles from surface of in-
fected cells? Our attempts to detect any GAG-degrading activity associated with HSV-2 
particles have failed. However, it has been recently reported that HSV enhanced expres-
sion of cellular heparanase, an enzyme that degrades HS chains thus liberating the virus 
particles trapped at the cell surface [14]. These authors found that the knockdown of hep-
aranase gene in cultured cells decreased the amount of liberated HSV-1 by ~4 fold. Our 
data indicate that the deficiency in mgG expression reduced the amount of HSV-2 released 
from GMK AH1 cells by ~200 fold. Furthermore muparfostat (PI-88), a known inhibitor of 
cellular heparanase [46], did not inhibit the HSV-2 release from cells but instead it sub-
stantially enhanced the amount of liberated virus. This suggests that besides an enzymatic 
degradation of GAG chains, the viral components such as mgG could be needed for effi-
cient release of HSV-2 virions. Indeed, an interaction between the virus attachment com-
ponents and GAG chains is known to be relatively weak and of electrostatic nature [47,48], 
and the GAG mimetics such as heparin and muparfostat, which are more extensively sul-
fated than GAG chains, may easily release the virus particles from their binding to GAGs. 
Our previous study [48] revealed that interaction of muparfostat with the HSV particles 
Figure 6. GMK AH1 cells were inoculated with the strain wt333, and 24 h later purified methyl-3H-
thymidine labeled mgG deficient or wild type virions (adjusted to 1.7 × 107 DNA copies) were added
and incubated with cells for 2 h at 37 ◦C. The results are expressed as a percentage of the number
of counts per minute (cpm) bound to infected cells rela ive to that bound to non-infected control
cells. Values shown are means (±SD) f data from two s parate experimen s performed in duplicates.
The mean number of cpm bound to non-infected cells were 1053 and 554 for wt333 and gG-def
virions respectively. Statistically significant differences as related to uninfected cells at p values of
<0.005 (***).
4. Discussion
We report that the mucin-like glycoprotein mgG of HSV-2 balances the virus interac-
tion with GAG chains, a feature r quired f r efficient release of progeny virions from the
surface of infected cells. This conclusion is deduced from the foll wing observations. The
amo nt of infectious virus that was spontaneously released from cells i to extracellular
m dium was substantially decreased in the mgG deficient mutant virus as related to native
HSV-2, a difference reversed to nativ HSV-2 level by restoration of the mgG expression in
the virus mutant. This differ nce cann t be attributed to a defect in production of infectious
virus since a total yield of the mgG deficient mutant was only ~4–6 times lower than that
of native HSV-2. Moreover, our data exclude the possibility that the poor release of gG
deficient HSV-2 from cells was caused by an altered production of viral Us3, a protein
expressed from the same bicistronic gene as gG. It is not known whether the coupled
expression of Us3 and gG has any biological significance, however, Us3 protein kinase is a
known anti-apoptotic component of HSV-2 [45].
How does the mgG of HSV-2 promote release of virus particles from surface of infected
cells? Our attempts to detect any GAG-degrading activity associated with HSV-2 particles
have failed. However, it has been recently reported that HSV enhanced expression of
cellular heparanase, an enzyme that degrades HS chains thus liberating the virus particles
trapped at the cell surface [14]. These authors found that the knockdown of heparanase
gene in cultured cells decreased the amount of liberated HSV-1 by ~4 fold. Our data
indicate that the deficiency in mgG expression reduced the amount of HSV-2 released from
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GMK AH1 cells by ~200 fold. Furthermore muparfostat (PI-88), a known inhibitor of cellu-
lar heparanase [46], did not inhibit the HSV-2 release from cells but instead it substantially
enhanced the amount of liberated virus. This suggests that besides an enzymatic degrada-
tion of GAG chains, the viral components such as mgG could be needed for efficient release
of HSV-2 virions. Indeed, an interaction between the virus attachment components and
GAG chains is known to be relatively weak and of electrostatic nature [47,48], and the GAG
mimetics such as heparin and muparfostat, which are more extensively sulfated than GAG
chains, may easily release the virus particles from their binding to GAGs. Our previous
study [48] revealed that interaction of muparfostat with the HSV particles is reversible and
non-virucidal and a simple dilution of the virus-muparfostat mixture liberated infectious
virus. Furthermore, some intrinsic features of mucin-like proteins may promote the re-
versibility of this binding. In particular, the mucin-like region forms an extended structure
due to the presence of numerous O-linked glycans that are frequently terminated with a
negatively charged sialic acid residue. Hence, both steric hindrance from this extended
domain and electrostatic repulsion between the sialic acid coat and the negatively charged
sulfate/carboxylate groups of GAG chains can contribute to the reversibility of the virus
binding to GAGs. Since the GAG chains are ubiquitous components of the cell surface,
the reversibility of the virus-GAG interaction may counteract trapping of viral particles
engaged in non-productive dead-end interactions that prematurely terminates the virus
life cycle at the stage of virus attachment to cells or release of progeny virions from the
surface of infected cells.
Machiels et al. [49] reported that bovine herpesvirus 4, lacking the mucin-like protein
gp180, showed enhanced susceptibility to neutralization by immune sera. Since gC and
gB are the GAG-binding components of HSV-2 [32] and the latter protein was reported to
mediate the binding of HSV-2 to cells [50], mgG together with gC and gB may form an
attachment complex that both promotes and balances the virus interaction with GAGs.
Indeed, we have previously found that mgG preserves specific sensitivity of HSV-2 to
the GAG-mimicking inhibitors of virus attachment to cells [16]. More importantly, the
absence of mgG in virus particles seems to unbalance the virus binding to GAGs, a notion
strongly supported by our analysis of interaction between HSV-2 and surface-immobilized
CS chains, demonstrating a clearly enhanced association to the GAGs for the mgG defi-
cient virus particles in comparison to the native HSV-2 virus particles. In addition, we
demonstrated that CS-bound HSV-2 particles undergo lateral diffusion, a feature that we
already reported for HSV-1 [38]. Remarkably, the diffusive activity of the GAG-bound
virions appeared to be compromised for mgG deficient mutant virus particles. Although
reasons behind this poor mobility of the mgG deficient virions require further clarification
it is likely that the lack of the mucin-like mgG protein may facilitate accessibility and/or
may enhance capability of the major virus attachment components gB and gC to interact
with the GAG layer, a possibility supported by the observed increase in the CS-mgGdef
association rates. This effect could in turn lead to an increased number of bonds between
the individual virions and the CS chains and thereby compromise the lateral diffusion
of the virions. Another possible explanation could be that the mgG glycoprotein itself,
through interaction with the GAG chains, plays a role in guiding the virus movement on
the cell surface. We believe that the extensive GAG-binding capability that compromised
lateral diffusion could also be detrimental for the liberation of the mgG deficient viral
particles from the surface of infected cells. This interpretation seems to be in line with our
data showing the defect in release of mgG deficient virus particles from sog9 cells which
express truncated variants of CS chains as the only type of sulfated GAGs [43]. Moreover,
our data showing that the mgG deficient mutant virus, unlike native HSV-2, bound to in-
fected cells as efficiently as to non-infected cells strongly suggest that the viral particles that
lack mgG are greatly unbalanced and vulnerable to unfavorable or premature interactions
with infected cells. The capability of ionic compounds such as GAG mimetics to liberate
this virus suggests that the trapping of the mgG deficient virus is based on its reversible
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electrostatic interactions with GAGs. However, one cannot exclude that this mutant virus
may bind to other negatively charged cellular components of unknown identity.
Besides viral particles, the mgG was abundantly expressed on the plasma membrane
of infected cells including cytoplasmic protrusions. This arrangement is similar both to
cellular sialomucins which are known to be extensively expressed on microvillus pro-
trusions [51,52] and to the viral mucin-like proteins such as gp2 of equine herpesvirus 1
(EHV-1) [53] and gp150 of murine herpesvirus 4 (MHV-4) [54] that are regarded as the
major virus antigens. Abundant expression at the cell plasma membrane of infected cells
was also reported for gD of HSV-1 [55], an event related to possible blockage of the viral
entry receptors and interference with HSV re-infection [56,57]. It is not known whether
extensive expression of mgG on cellular protrusions coincides with the expression of the
HSV attachment receptors that is, the GAG-bearing proteoglycans, however, these proteins
are known to stabilize the structure of cellular microvillus protrusions (reviewed in [58]).
An abundant expression of mgG may protect infected cells against immune response or
may help to release an entire infected cell. Transmission of viral infection through infected
cells is a known mode of the host-to-host spread of sexually transmitted pathogens [59].
In HSV-1, the mucin-like domain occurs in the amino-terminal portion of the virus
attachment protein gC, and our previous data [60] indicate that this region of gC of HSV-1
functions in balancing the virus-GAG interaction and to some extent in promoting the
virus release from the surface of infected cells, that is biological activities similar to these of
mgG of HSV-2.
It is worth noting that the mgG deficient mutant of HSV-2 shows significant “func-
tional” similarity to variants of other herpesviruses lacking a specific mucin-like protein. In
particular, EHV-1 deficient in heavily O-glycosylated glycoprotein gp2, exhibited like the
mgG deficient HSV-2 an ~250 fold decrease in the amount of infectious virus released into
culture medium while a total virus yield was only 5 times less than that of native virus [61].
Furthermore, MHV-4 lacking an extensively O-glycosylated glycoprotein gp150 exhibited
severe defect in the virus release from the surface of infected cells documented as virion
clustering on the cell plasma membrane in form of several layers of tightly packed virus
particles [13]. In case of the mgG deficient mutant we did not observe such massive accu-
mulation of virus particles on the cell surface because this virus produced less infectious
virus than native HSV-2. One consequence of the impaired release of the mgG deficient
HSV-2 (this report), as well as EHV-1 and MHV-4 mutants described above [13,61] is that all
these viruses spread mainly through the direct cell-to-cell contact with little dissemination
via release and re-adsorption to non-infected cells.
Altogether, our data indicate that the mucin-like envelope protein mgG preserves
specificity of the HSV-2 interaction with cell surface GAGs. This activity of mgG seems
to include prevention of excessive binding of viral particles to cells and promotion, in a
non-enzymatic manner, of its release from infected cells. Our study provides new insights
into the biological functions of viral mucin-like proteins that can be exploited in antiviral
and vaccine research.
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